freeze-thaw is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Doxepin is a medication belonging to the tricyclic antidepressant (TCA) class of drugs used to treat major depressive disorder, anxiety disorders, difficult-to-treat chronic urticaria, and insomnia. For hives it is a less preferred alternative to antihistamines. It has a mild to moderate benefit for sleeping problems. It is used as a cream for itchiness due to atopic dermatitis or lichen simplex chronicus. Common side effects include sleepiness, dry mouth, constipation, nausea, and blurry vision. Serious side effects may include increased risk of suicide in those under the age of 25, mania, and urinary retention. A withdrawal syndrome may occur if the dose is rapidly decreased. Use during pregnancy and breastfeeding is not generally recommended. Although how it works for treating depression remains an area of active inquiry, it may involve increasing the levels of norepinephrine, along with blocking histamine, acetylcholine, and serotonin. Doxepin was approved for medical use in the United States in 1969. It is available as a generic medication. In 2023, it was the 166th most commonly prescribed medication in the United States, with more than 3 million prescriptions.
A 2021 poll by WR Numero Research revealed that 54.59% of voters want soft continuity of Duterte's policies, 29.57% want full continuity, while only 15.84% preferred change. Duterte left office with a net satisfaction rating of 81%, his highest in SWS polling. Additionally, polling firm PUBLiCUS Asia reported in Duterte's last month in office that Duterte received a 75% approval for his entire six-year tenure, making him the most popular post-EDSA president.
The introductions of Mia and Chloe helped further exploration of Ari's fictional backstory. It emerges that after their baby son died, Ari's grief caused him to self-destruct and he was later sent to prison for 10 years. Mia then chose to move away with Chloe, who lost the only father figure she had ever known. Ari is surprised when Chloe turns up in the Bay to see him, and he soon learns that Mia lied to Chloe about why he left them, saying that he did not want to be in their lives anymore. Kipa-Williams explained: "Just before her 10th birthday, Ari ended up getting arrested armed robbery and he went to jail. This left Chloe feeling very confused and hurt as to why he never came back home." The actor also said that Ari has mixed emotions about Chloe's arrival, as he knows that Mia will be close behind her and he is unsure about facing his past so soon. Mia turns up at Ari's door just as he is telling Mac about their history. Kipa Williams branded the exes "star-crossed lovers" and said they had a long history together. Ari knows that things were left unresolved between them and Kipa Williams believed that Ari never stopped loving Mia. After he breaks up with Mac, Ari has an awkward meeting with Mia in the gym. Kipa-Williams explained: "Ari doesn't actually tell Mia he's broken up with Mac, so Mia remains guarded and communicates with him like he's still in a relationship." While Kipa-Williams was disappointed about the end of Ari and Mac's relationship, he relished the opportunity to explore his character's background further with Mia and Chloe.
Sources: en.wikipedia.org
Shalek (2004), professor at Institute for Medical Engineering and Science, Massachusetts Institute of Technology Kerstin Perez (2005), particle physicist and professor at Columbia University Daniel Harlow (2006), professor at Massachusetts Institute of Technology, winner of the 2019 New Horizons in Physics Prize Aaron Roth (2006), professor of computer science at University of Pennsylvania Andrea Young (2006), experimental physicist at the University of California, Santa Barbara, winner of the 2018 New Horizons in Physics Prize Julia Kalow (2008), chemist, professor at Northwestern University Calvin Sun (2008), emergency room doctor known for his first-hand reporting on the COVID-19 pandemic in New York City
=== Air purifier distribution === On Friday, July 21, 2023, Illinois Governor JB Pritzker and the Illinois Department of Public Health announced they were partnering with SHIELD Illinois to distribute air purifiers to licensed Illinois Day Care outside of the city of Chicago. The purifiers were purchased with $10 million of federal funds through the CDC's Epidemiology and Laboratory Capacity for Prevention and Control (ELC) Reopening Schools Program. SHIELD Illinois will use the extensive logistics capabilities developed serving over 2,300 locations during the pandemic to distribute the filters across the state.
== External links == Brain+Natriuretic+Peptide at the U.S. National Library of Medicine Medical Subject Headings (MeSH) BNP and NT-proBNP at Lab Tests Online Human NPPB genome location and NPPB gene details page in the UCSC Genome Browser. Overview of all the structural information available in the PDB for UniProt: P16860 (Natriuretic peptides B) at the PDBe-KB.
Sources: en.wikipedia.org
== Licenses == As of 2025, a plurality (39%) of models released on Hugging Face used the permissive Apache 2.0 License. Some models, such as the source-available Llama 3, have licenses that grant some of the benefits of open-source licenses, but also contain legal restrictions that deter some companies from using those models, as the companies fear a future lawsuit or a change in the terms and conditions. Some of the same fears also exist in the large number of smaller models that do not specify a license.
Insect pests such as the potato tuber moth and Colorado potato beetle, which are predicted to spread into areas currently too cold for them. Aphids which act as vectors for many potato viruses and will spread under increased temperatures. Pathogens causing potato blackleg disease (e.g. Dickeya) grow and reproduce faster at higher temperatures. Bacterial infections such as Ralstonia solanacearum will benefit from higher temperatures and spread more easily through flash flooding. Late blight benefits from higher temperatures and wetter conditions. Late blight is predicted to become a greater threat in some areas (e.g. in Finland) and become a lesser threat in others (e.g. in the United Kingdom).
== Pathology == Mutations in the gene for StAR cause lipoid congenital adrenal hyperplasia (lipoid CAH), in which patients produce little steroid and can die shortly after birth. Mutations that less severely affect the function of StAR result in nonclassic lipoid CAH or familial glucocorticoid deficiency type 3. All known mutations disrupt StAR function by altering its START domain. In the case of StAR mutation, the phenotype does not present until birth since human placental steroidogenesis is independent of StAR. At the cellular level, the lack of StAR results in a pathologic accumulation of lipid within cells, especially noticeable in the adrenal cortex as seen in the mouse model. The testes are undescended and the resident steroidogenic Leydig cells are modestly affected. Early in life, the ovary is spared as it does not express StAR until puberty. After puberty, lipid accumulations and hallmarks of ovarian failure are noted.
== List of major publications in English == Vladimir Kh. Khavinson. Peptides and Ageing. // Neuroendocrinology Letters. — Vol. 23, Suppl. 3, Special Issue. — 2002. — 144 p. Khavinson, Malinin. Gerontological Aspects of Genome Peptide Regulation. // Basel (Switzerland): Karger AG. — 2005. — 104 p. Khavinson. Peptidergic regulation of ageing. // SPb.: Humanistica. — 2009. — 48 p. Khavinson, Morozov, Anisimov. Experimental Studies of the Pineal Gland Preparation Epithalamin. // The Pineal Gland and Cancer. — Bartsch C., Bartsch H., Blask D.E., Cardinali D.P., Hrushesky W.J.M., Mecke D. (Eds.) — Springer-Verlag, Berlin, Heidelberg. — 2001. — P. 294–306. Vladimir N. Anisimov, Vladimir Kh. Khavinson. Small Peptide-associated Modulation of Aging and Longevity. // Modulating Aging and Longevity. — Kluwer Academic Publishers (Printed in the United Kingdom) — Suresh I.S. Rattan (ed.). — 2003. — P. 279–301. Vladimir N. Anisimov, Vladimir Kh. Khavinson. Pineal Peptides as Modulators of Aging. // Aging Interventions and Therapies. — World Scientific. — Suresh I.S. Rattan (ed.). — 2005. — P. 127–146. Khavinson, Mikhailova. Health and Aging in Russia. // Global Health and Global Aging. / (ed. by Mary Robinson et al.); foreword by Robert Butler. — 1st ed. — 2007. — P. 226–237. Khavinson, Neroev, Trofimova, Osokina. Unique method for restoration of retinal functions in case of different diseases. // SPb. — 2011. — 32 p.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.